Intarcia Therapeutics and the California Institute for Biomedical Research said today that the 2 groups will collaborate to develop a peptide therapeutic for patients with type II diabetes and obesity. The drug will be derived from Calibr’s stapled-peptide technology platform, combined with Intarcia’s late stage investigational GLP-1 therapy and delivered using the match-sized Medici osmotic pump.
According to the deal, Calibr will receive an upfront grant of Intarcia equity and additional shares vesting over key development milestones. Calibr could also earn undisclosed cash payments after reaching predetermined regulatory and sales milestones, as well as tiered royalties on product sales.
Get the full story at our sister site, Drug Delivery Business News.
The post Intarcia, Calibr collaborate to develop peptide therapeutic for Medici pump appeared first on MassDevice.